A phase IB/IIA study of remestemcel‐L, an allogeneic bone marrow‐derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis

AIM: There have been no studies into the direct injection of mesenchymal stem cells (MSCs) for luminal ulcerative colitis (UC). Our aim was to investigate the efficacy of MSCs delivered locally via endoscopic delivery, as is done in the setting of perianal disease, to treat the local site of inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lightner, Amy L., Dadgar, Neda, Matyas, Caroline, Elliott, Kavita, Fulmer, Clifton, Khaitan, Neha, Ream, Justin, Nachand, Douglas, Steele, Scott R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795998/
https://www.ncbi.nlm.nih.gov/pubmed/35767384
http://dx.doi.org/10.1111/codi.16239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795998/
https://www.ncbi.nlm.nih.gov/pubmed/35767384
http://dx.doi.org/10.1111/codi.16239

Ejemplares similares